Provided by Tiger Trade Technology Pte. Ltd.

Spero Therapeutics Inc.

1.21
-0.0100-0.82%
Post-market: 1.210.00000.00%19:43 EDT
Volume:362.98K
Turnover:434.75K
Market Cap:70.46M
PE:9.47
High:1.22
Open:1.20
Low:1.19
Close:1.22
52wk High:3.08
52wk Low:1.08
Shares:58.23M
Float Shares:45.59M
Volume Ratio:1.29
T/O Rate:0.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1278
EPS(LYR):0.1500
ROE:19.17%
ROA:7.19%
PB:1.59
PE(LYR):8.07

Loading ...

Spero Therapeutics - Proceeds to Support Advancement of Lead Immunology Drug Candidate SP001

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - to Retain 35% of Subsequent GSK Payments Related to Utebzi Sales After Repayment

THOMSON REUTERS
·
Jul 14

Spero Therapeutics Announces $105 Million Non-recourse Non-dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - Hcrx to Receive Quarterly Principal and Interest Payments Derived from the GSK Payments Due to Spero Until Loan Repaid

THOMSON REUTERS
·
Jul 14

Innovent Biologics Licenses Anti-cd40l Antibody Ibi355 to Spero in Deal Worth About USD 1.1 Billion

Reuters
·
Jul 14

Spero Therapeutics - Innovent to Receive Payments Totaling About $1.1 Bln Plus Tiered Royalties

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - Innovent to Initiate Phase 2 Trial for Sjögren’s Disease in China by Early 2027

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - to Initiate Phase 2 Trial for SP001 in Igg4-rd in Q2 2027

THOMSON REUTERS
·
Jul 14

Innovent Biologics - Spero Receives Exclusive Global Rights to Ibi355 Excluding Greater China

THOMSON REUTERS
·
Jul 14

Innovent Biologics and Spero Therapeutics Announce Exclusive License for Ibi355 (sp001), a Phase 2-ready Third-generation Anti-cd40l Antibody

THOMSON REUTERS
·
Jul 14

Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors

GlobeNewswire
·
Jul 08

Spero Therapeutics Shareholders Approved Increase in Authorized Common Shares to 240 Million

Reuters
·
Jun 26

Spero Therapeutics says FDA approves Utebzi oral antibiotic for complicated UTIs in adults

Reuters
·
Jun 23

GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections

MT Newswires Live
·
Jun 18

GSK Says cUTI Oral Antibiotic Tebipenem Approved By US FDA

Reuters
·
Jun 17

GSK, Spero Therapeutics announce FDA approval of Utebzi

TIPRANKS
·
Jun 17

US FDA approves GSK's oral antibiotic for drug-resistant UTIs

Reuters
·
Jun 17

BRIEF-FDA Approves First Oral Carbapenem Therapy For Complicated Urinary Tract Infections

Reuters
·
Jun 17

GSK - Tebipenem Pivoxil Expected to Be Available in US by End of 2026

THOMSON REUTERS
·
Jun 17

Promising Penny Stocks To Consider In May 2026

Simply Wall St.
·
May 15